Skip to main
SMTI
SMTI logo

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc. demonstrated substantial financial growth, with revenue from soft tissue repair products reaching $22.7 million, reflecting a 28% year-over-year increase primarily fueled by rising demand for CellerateRX Surgical Activated Collagen. Additionally, the company's bone fusion products generated $3.1 million in revenue, marking a 25% year-over-year growth, indicating strong performance across multiple product lines. The ongoing strategy to expand distribution partnerships and penetrate healthcare facilities positions Sanara MedTech for continued revenue growth in the future.

Bears say

Sanara MedTech faces several significant risks that contribute to a negative outlook on its stock, primarily centered around lower-than-projected revenue growth from its product portfolio. The company may struggle to secure additional customers, which could hinder its market expansion and revenue potential. Furthermore, the inability to successfully launch new products or services poses a threat to its competitive positioning in the medical technology sector, while potential dilution risks could adversely affect shareholder value.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.